Rolling Stone: Pot For All

This piece was originally published by Rolling Stone. Click here to view the article.

Pot for All: How Congress Is Trying to Make Weed Legal


From decriminalization to opening up the banking industry, both sides of Congress are preparing cannabis bills – but with much different approaches.


Over the past decade, marijuana legalization has happened at break-neck speed at the state and local level. And yet, pot-related reforms have moved glacially at the federal level, especially since prohibitionist Jeff Sessions was confirmed as attorney general. But his staunch opposition and attempt to roll back Obama-era protections for local marijuana businesses has actually attracted new support to a flurry of marijuana related bills that have been picking up support in this Congres

There are more than 40 cannabis-related bills floating around the House of Representatives alone in this Congress, along with countless others in the Senate. That’s a hard map to navigate, so below is Rolling Stone’s guide to the kinds of marijuana bills that have the most support from Democrats and Republicans alike.

Straight Decriminalization

Senate Minority Leader Chuck Schumer turned heads last month when he endorsed marijuana decriminalization, but he was slow to get to the party. Vermont’s Bernie Sanders was there before him, along with most every Democratic senator floated as a potential 2020 presidential contender, including Sens. Cory Booker (NJ), Kamala Harris (CA) and Kirsten Gillibrand (NY). Still, the statement from Schumer – who has long vocally opposed recreational marijuana – was witnessed as a dramatic move and is expected to trickle down the ballot to people running for Congress across the nation.

“This is something that is long overdue, and I would hope to see it happen,” Senate Minority Leader Chuck Schumer told Rolling Stone when asked about his newfound support for decriminalization at a recent Capitol Hill press conference. While numerous decriminalization bills already exist, Schumer’s office says he plans to introduce his own legislation on it, which they said would come on 4/20 and now they say will come at an unknown date.

But Schumer is in the minority party, and Senate Majority Leader Mitch McConnell, who currently controls floor time, isn’t budging on marijuana, even as he’s continuing his years-long push to legalize industrial hemp cultivation in the U.S.

“I do not have any plans to endorse legalization of marijuana,” McConnell responded to a question from Rolling Stone at the Capitol. “It may be good to point out again that these are two entirely separate plants. I hope everybody now understands that.”

When McConnell dubbed marijuana – which, unlike hemp, contains enough THC to get you high – hemp’s “illicit cousin,” the press corps broke out in laughter. But Schumer wasn’t laughing when he heard McConnell wouldn’t be joining his new effort to decriminalize marijuana after he endorsed McConnell’s hemp bill.

“Aw, come on Mitch,” Schumer told reporters.

Let the States Decide

In the coming weeks, a bipartisan group of senators plans to drop a bill that will give individual states the right to override the federal prohibition on marijuana, which they say simply codifies what President Trump has allegedly told Sen. Cory Gardner (R-CO) in private conversations – that the president’s fine allowing each individual state to decide their own marijuana laws, which Gardner says is simple federalism.

“The president has said he would support a federalist approach to marijuana, and this embodies that approach,” Gardner tells Rolling Stone of his bill. He says he’s still working out the final details of it with Sen. Elizabeth Warren (D-MA). She’s become more emboldened on the issue since AG Sessions rescinded the so-called Cole Memo that directed federal prosecutors to not prioritize marijuana enforcement in states that legalized weed.

But some of Trump’s biggest fans are dubious of what other lawmakers report the commander-in-chief has said in private.

“I’d be very surprised if the president, given his family history and attitude towards addictive substances, would be overly willing to expand the legalization of a drug,” Rep. Andy Harris (R-MD) tells Rolling Stone.

Lawmakers are questioning its chances under this administration, especially because the attorney general has asked lawmakers to unwind the current congressional constraints that keep him from expending money on enforcing the federal marijuana ban in states that have legalized marijuana.

Make the Focus Medical Testing

Potentially the best chance marijuana legislation has of passing under unified Republican control of Washington is with bipartisan legislative efforts to simply relax the barriers that have been erected around studying marijuana.

There was already historic progress on that front when, earlier this month, the VA Medicinal Cannabis Research Act of 2018 became the first-ever standalone marijuana bill to make it through a congressional committee. It not only removes barriers to testing marijuana at the Department of Veterans Affairs but also forces officials there to send regular reports to Congress so lawmakers can track whether the VA is taking the testing legislation seriously. While the scope is narrow, pot proponents see the bill as a major breakthrough because, if tests show marijuana is good for veterans, then it could easily translate to the greater public.

“We shouldn’t have state legislatures deciding on what’s an adequate treatment for somebody,” Rep. Phil Roe (R-TN), who chairs the Veteran’s Affairs Committee, tells Rolling Stone. Roe – a doctor and staunch conservative from a state where a first-time offense for possession of less than a half ounce of weed can land you in jail for a year – says he merely wants to see evidence.

“I need to know what are the risks, the benefits, the doses, the black box warnings. Does it work better than placebo? Does it not?” he says. “I don’t know why we took so long to get here.”

As the administration is still winding down two foreign wars that maimed many of our citizens – including a few current lawmakers from both parties – supporters say now is the perfect time to test marijuana treatment on vets, especially those dealing with PTSD or relying on a heavy opioid cocktail to deal with chronic pain.

“Today in America, there are clinical trials that need veterans to participate, but at the VA today we’re not even able to tell veterans of the existence of those trials,” Rep. Matt Gaetz (R-FL) tells Rolling Stone.

Gaetz, a Tea Party darling who frequents the far right media circuit, says that while the dam is breaking slowly, a flood could well be coming. He says Exhibit A is the Medical Cannabis Research Act of 2018, which has support from some of the staunchest conservatives in the Capitol. Like the veterans bill, it simply allows more research to be done on weed. Gaetz says the broad support behind that bill shows the times have changed.

Push for Access to Banks

Marijuana businesses are currently locked out of the banking sector, even in states where weed is either recreationally or medicinally legal, and the Small Business Administration recently moved to stop any company involved in this green revolution from receiving loans. Bipartisan efforts are picking up steam to at least make it so marijuana businesses don’t have to be all cash, which comes with massive security risks. And without access to capital it’s hard to be a player in a capitalistic economy. A slew of bills deal with this issue – some allow marijuana businesses to simply access the banking system, while others go farther, allowing them to get the same tax breaks enjoyed by non-marijuana related businesses.

“We just shouldn’t deny a wider range of business opportunities,” Rep. Earl Blumenauer (D-OR) tells Rolling Stone. “And it’s not just people who cultivate – there are people who provide facilities, equipment, professional services. I mean it’s insane.”

Finally De-Scheduling Pot

Support is also slowly growing for an effort to completely remove marijuana from the list of controlled substances where it currently sits at Schedule I, alongside LSD and heroin. But the Marijuana Justice Act goes even further and takes aim at the racial disparity that marks American prisons by expunging the records of people convicted of federal marijuana crimes and investing money in communities left blighted by marijuana convictions.

Last summer, the Justice Act was introduced by Democratic Sen. Booker of New Jersey in the upper chamber and by Rep. Barbara Lee of California in the House – the first time both chambers have seen bills introduced to completely delist marijuana. It remains a long shot, but it’s picking up steam – and its supporters say this is just the beginning.

“The people are always ahead of their elected officials and, I think, what I see is the elected officials are catching up with the people,” Lee tells Rolling Stone. “So, that’s why I’m so excited about the movement that has got us this far. I want to encourage everyone to get to their elected officials, get to their members of Congress and tell them what this is about and why this needs to pass.”


Please read these terms and con­di­tions fully and care­fully. If you do not agree to be bound to each and every term and con­di­tion set forth herein, please exit the Site and do not access, read or oth­er­wise use infor­ma­tion pro­vided herein.

The blog pro­vides only gen­eral infor­ma­tion and dis­cus­sion about med­i­cine, health and related sub­jects. Any views or opinions represented in this blog are personal and belong solely to the specific author and do not represent those of people, academic, hospital, practice or other institutions or organizations that the author may or may not be associated with in professional or personal capacity, and do not represent the views or opinions of GB Sciences, Inc., unless explicitly stated.

The words and other con­tent pro­vided in this blog, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. Noth­ing con­tained in the Site is intended to estab­lish a physician-patient rela­tion­ship, to replace the ser­vices of a trained physi­cian or health care pro­fes­sional, or oth­er­wise to be a sub­sti­tute for pro­fes­sional med­ical advice, diag­no­sis, or treatment. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other health care worker. The information is provided by the specific author and the author makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the information, products, services, or related graphics contained in the blog for any purpose. Any reliance placed on such information is therefore strictly at the reader’s own risk.

This blog may contain statements that could be construed to relate to future results or events. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the specific author’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the specific author’s control. The specific author’s beliefs are not the beliefs of GB Sciences, Inc., and do not represent the views or opinions of GB Sciences, Inc., unless explicitly stated.

It is possible that the actual results and financial condition of GB Sciences, Inc., may differ, possibly materially, from the anticipated results and financial conditions suggested in these forward-looking statements by the blog author. Information concerning the GB Sciences, Inc., and its business, including factors that potentially could materially affect GB Sciences, Inc., are contained in the company’s filings with the Securities and Exchange Commission, available at  Any forward-looking statements included in this blog are made only as of the date of this blog, and neither the specific blog author nor GB Sciences, Inc., undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which they may hereafter become aware.

Through this website and blog you are able to link to other websites that are not under the control of the blog author or GB Sciences, Inc. The blog author and GB Sciences, Inc., have no control over the nature, content and availability of those sites. The inclusion of any links does not imply a recommendation or endorsement of the views and opinions expressed within them.

Con­tent made avail­able at the Site is pro­vided on an “as is” and “as avail­able” basis with­out war­ranties of any kind, either express or implied. Under no cir­cum­stances, as a result of your use of the Site, will the specific author or GB Sciences, Inc., be liable to you or to any other per­son for any direct, indi­rect, inci­den­tal, con­se­quen­tial, spe­cial, exem­plary or other dam­ages under any legal the­ory, includ­ing, with­out lim­i­ta­tion, tort, con­tract, strict lia­bil­ity or oth­er­wise, even if advised of the pos­si­bil­ity of such damages.

By access­ing the Site and/or read­ing its con­tent, you acknowl­edge and agree that you have read and under­stand these terms and con­di­tions, that the pro­vi­sions, dis­clo­sures and dis­claimers set forth herein are fair and rea­son­able, and that your agree­ment to fol­low and be bound by these terms and con­di­tions is vol­un­tary and is not the result of fraud, duress or undue influ­ence exer­cised upon you by any per­son or entity.